# Long-term Safety Study of Alogliptin in Participants With Type 2 Diabetes in Japan

> **NCT01263496** · PHASE2 · COMPLETED · sponsor: **Takeda** · enrollment: 438 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** Alogliptin
- **DRUG:** Alogliptin
- **DRUG:** Alogliptin
- **DRUG:** Alogliptin
- **DRUG:** Voglibose

## Key facts

- **NCT ID:** NCT01263496
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-05
- **Primary completion:** 2008-09
- **Final completion:** 2008-09
- **Target enrollment:** 438 (ACTUAL)
- **Last updated:** 2012-02-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01263496

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01263496, "Long-term Safety Study of Alogliptin in Participants With Type 2 Diabetes in Japan". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01263496. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*